Bioatla, Inc.
Clinical trials sponsored by Bioatla, Inc., explained in plain language.
-
New hope for lung cancer patients who stopped responding to standard treatments
Disease control CompletedThis study tested a new drug, BA3011, alone or with an immunotherapy (PD-1 inhibitor) in 85 adults with advanced non-small cell lung cancer that had stopped responding to prior treatments. The goal was to see if the drug could shrink tumors and to check for side effects. The stud…
Phase: PHASE2 • Sponsor: BioAtla, Inc. • Aim: Disease control
Last updated May 26, 2026 10:16 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called mecbotamab vedotin, given alone or with another drug (nivolumab), in 245 people aged 12 and older with advanced solid tumors like sarcoma. The goal was to see if the drug is safe and shrinks tumors. Researchers measured side effects and how man…
Phase: PHASE1, PHASE2 • Sponsor: BioAtla, Inc. • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug shows promise for tough head and neck cancers
Disease control CompletedThis study tested a new drug called ozuriftamab vedotin in 42 people with head and neck cancer that had come back or spread. The goal was to see if the drug could shrink tumors and how safe it was. Researchers measured how many patients responded to treatment and tracked side eff…
Phase: PHASE2 • Sponsor: BioAtla, Inc. • Aim: Disease control
Last updated May 22, 2026 13:53 UTC